| Ytd | 10.05% | |
| 1y | 8.53% |
| Open | 29.04 | Prev Close | 29.30 | Low | 28.88 | High | 30.25 | Mkt Cap | 2.35B |
| Vol | 992.78K | Avg Vol | 1.32M | EPS | -4.44 | P/E | N/A | Forward P/E | -7.06 |
| Beta | 0.90 | Short Ratio | 12.63 | Inst. Own | 110.27% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-09 | 50-d Avg | 37.87 | 200-d Avg | 32.44 | 1yr Est | 63.07 |
CLDX News
Celldex Therapeutics (NASDAQ: CLDX - Get Free Report) and Senti Biosciences (NASDAQ: SNTI - Get Free
HC Wainwright & Co. analyst Joseph Pantginis reiterates Celldex Therapeutics (NASDAQ:CLDX) wi
Leerink Partners analyst Thomas Smith maintains Celldex Therapeutics (NASDAQ:CLDX) with a Outperf
Morgan Stanley analyst Judah Frommer maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweig
U.S. stocks were mixed: Nasdaq and S&P 500 rose while the Dow fell; communication services gaine
Celldex posts positive Phase 3 data for barzolvolimab to treat chronic spontaneous urticaria. The co
HC Wainwright & Co. analyst Joseph Pantginis maintains Celldex Therapeutics (NASDAQ:CLDX) wit
Cantor Fitzgerald analyst Kristen Kluska maintains Celldex Therapeutics (NASDAQ:CLDX) with a Over
Gainers Decoy Therapeutics (NASDAQ:DCOY) shares rose 84.0% to $4.71 during Tuesday's pre-market
EMBARQ-CSU1 and -CSU2 met primary and all key secondary endpoints at 12 weeks across both studies an
Morgan Stanley analyst Judah Frommer maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweig
Morgan Stanley analyst Judah Frommer maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweig
Barclays analyst Etzer Darout maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and
Celldex Therapeutics (NASDAQ:CLDX) reported quarterly losses of $(0.94) per share which beat the ana
Wells Fargo analyst Derek Archila maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight
Wells Fargo analyst Derek Archila maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight
Morgan Stanley analyst Judah Frommer maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweig
Pegasystems Inc (NASDAQ: PEGA) reported lower-than-expected earnings and sales, causing stocks to fa
Cantor Fitzgerald analyst Kristen Kluska maintains Celldex Therapeutics (NASDAQ:CLDX) with a Over
Celldex has discontinued its Phase 2 trial of barzolvolimab for prurigo nodularis after failing to m
Canaccord Genuity analyst Edward Nash maintains Celldex Therapeutics (NASDAQ:CLDX) with a Buy and
Study did not meet key efficacy objectivesFavorable safety profile consistent with prior studies, in
Guggenheim analyst Yatin Suneja maintains Celldex Therapeutics (NASDAQ:CLDX) with a Buy and raise
Wall Street rebounded on Monday, recovering part of last week's steep losses as investors grew m
Jasper Therapeutics reports strong briquilimab efficacy in CSU with UAS7 reductions, dose-dependent
Gainers Carbon Revolution Public Limited (NASDAQ: CREV) shares jumped 396.2% to $145.49 after ga
During the session on Thursday, 461 stocks hit new 52-week lows.
During Tuesday's session, 275 companies made new 52-week lows.
During Monday's trading, 1214 companies set new 52-week lows.
On Friday, 422 stocks made new 52-week lows.
During the Thursday's session, 100 stocks hit new 52-week lows.
Gainers TherapeuticsMD, Inc. (NASDAQ: TXMD) shares climbed 364% to close at $9.93 on Tuesday afte
Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to repo
Upgrades
Before 10 a.m. ET on Thursday, 91 companies hit new 52-week highs.
During Tuesday's morning session, 95 companies made new 52-week highs.
On Thursday morning, 159 companies achieved new highs for the year.
Before 10 a.m. ET on Tuesday, 128 companies hit new 52-week highs.